CareersInvestor RelationsPress RoomCOVID-19
  1. Home
  2. Laboratory Diagnostics
  3. Drug Testing Diagnostics
  4. Drug Testing Assays
  5. Therapeutic Drug Monitoring

Therapeutic Drug MonitoringPersonalized care starts with a test.

TDM Assay menu

Amikacin

Caffeine

Carbamazepine

Digoxin

Disopyramide†

Ethosuximide†

Gabapentin‡

Gentamicin

Lamotrigine‡

Levetiracetam‡

Lidocaine

Methotrexate (EMIT)

Methotrexate II*

N-Acetylprocainamide (NAPA)†

Phenobarbital

Phenytoin

Primidone

Procainamide†

Quinidine†

Theophylline

Tobramycin†

Topiramate‡

Valproic Acid

Vancomycin

Voriconazole‡

Zonisamide‡

*
Application manufactured by third party, distributed by Siemens Healthineers. 
†
User-defined method that is neither validated nor approved by Siemens Healthineers.
‡
Third-party, user-defined method that is neither validated nor approved by Siemens Healthineers.

Anti-inflammatory/Oncology

  • High-dose methotrexate (MTX) therapy is a key therapeutic agent for treating numerous types of cancer in both children and adults.
  • High-dose methotrexate therapy can be highly cytotoxic and carries risk of severe or fatal damage to the kidneys, liver, heart, GI tract and skin.
  • In addition to its use in oncology, MTX is often considered a first-line treatment for many autoimmune inflammatory disorders.
  • Laboratory evaluation plays a key role in patient care.

Now available! Methotrexate II Assay*

Illustration of test tubes in a rack representing therapeutic drug monitoring and immunosuppressant drug testing

Essential monitoring for treatment

Methotrexate treatment prevents harmful toxicity and results in patient compliance.

Illustration of a dashboard displaying assay performance data and analytics

Enhanced assay performance

With ready-to-use reagent, Methotrexate II Assay application provides improved precision, linearity, and sensitivity.

Illustration of a laboratory professional operating an analyzer for methotrexate monitoring

Making methotrexate monitoring routine

Simplifies integration into your clinical laboratory workflow.

Key Benefits:

  • Liquid-stable, ready-to-use reagents
  • Monoclonal antibody technology provides Improved precision and linearity
  • Enhanced sensitivity with extended range of detection (0.030-1.30 mmol/L)
  • Improved on-board stability (up to at least 60 days) 
  • Lower cross-reactivity with structurally related 7-hydroxymethotrexate (≤0.01%)
*
Now available on the Atellica DT 250 Analyzer and Atellica CH 930 Analyzer.
Validated application on the Atellica CI Analyzer pending upcoming software release.

Anti-seizure medications

Anti-seizure medication (ASM*) therapy is the primary modality for mitigating symptoms and managing disease. Second-generation ASMs such as levetiracetam and lamotrigine are now widely prescribed compared to first-generation ASMs (e.g., valproic acid, carbamazepine, and phenytoin), as they offer significant benefits to patients, including fewer severe side effects, a better safety profile (e.g., during pregnancy), and greater tolerability in general.

Siemens Healthineers offers a broad portfolio of assays for therapeutic drug monitoring, including levetiracetam and lamotrigine.

*
ASM is the preferred term to the older nomenclature of antiepileptic drugs (AEDs).
The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.